hanges calculated using 2010 non-GAAP net income and 2009 GAAP net income. No adjustment to net income was necessary in fiscal 2009."Our business strategy was very successful this year, as evidenced by strong double-digit annual growth in both our top and bottom lines and an especially strong fourth quarter," commented Mr. Yin Wang, Chairman and CEO of Weikang. "Our market share continues to improve with our successful new product launches and expanded sales channels. The five new products we launched during 2010 contributed roughly $11 million to our total sales, and we plan to launch four new products during 2011, three of which we expect to roll out during the first quarter."
Mr. Wang continued, "We are committed to implementing improved marketing and promotional strategies as well as aggressive R&D, both of which contributed to our strong performance this year. Furthermore, we have streamlined our cost structure in order to provide the highest quality product at the best value, and we look forward to continued growth of this nature as we continue to pursue additional US investor support and interaction in 2011."
Fiscal Year 2010 Results of OperationsRevenuesDuring the year ended December 31, 2010, the Company recorded record revenues of $74.6 million, compared to $47.5 million in 2009, an increase of 57.0%, or $27.1 million. The increase in sales was primarily attributable to sales of the Company's five new products launched in the second half of 2010, which accounted for approximately 15% of total revenues. An additional 8% of sales were attributable to new sales channels in Hunan and Guangxi provinces, with further growth due to increased client demand and market share. General price increases throughout China also contributed to higher product prices for the Company.
Gross ProfitCost of sales increased to $29.5 million in 2010 from $21.6 million in 2009. The increase of $7.9 million, or 36.5%, was mainl
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE Weikang Bio-Technology Group Co., Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance2
. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 20103
. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results4
. ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air5
. American Oriental Bioengineering Announces US$20 Million Share Repurchase Program6
. Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication7
. Cord Blood America Announces Affiliate Program to Educate on Value of Umbilical Cord Blood Stem Cell Storage8
. Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science9
. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform10
. Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA11
. Seattle BioMed Announces Major Scientific Expansion, New Addition to Leadership